Numerous biotechnology-related uses have an impact on our daily life. The use of genetically modified organisms and clinical trials greatly contributes to the development of food items, pharmaceuticals, agricultural products, and other products. Numerous entrepreneurs, particularly in the biopharmaceutical sector, are innovating and expanding the biotechnology sector while having a significant impact on several industries.
Biosplice Therapeutics is one such established startup with a global presence. By doing research and creating medications for osteoarthritis, cancer, neurology, and other degenerative conditions, it has grown into the most valuable US-based startup in the world.
Introducing Biosplice Therapeutics
A clinical-stage biotechnology business called Biosplice Medicines creates first-of-their-kind, small-molecule medicines based on the cutting-edge study of alternative pre-mRNA splicing for serious disorders.
The California-based company has early-stage studies in neurology and other critical unmet medical needs, as well as a focus on osteoarthritis and oncology. It uncovers fresh biological pathways and targets in the Wnt pathway to create small-molecule medications that could potentially treat a variety of degenerative diseases.
Biosplice Therapeutics: Biotechnology Industry
Biosplice Therapeutics works in the biotechnology sector, which is expected to grow at a phenomenal CAGR of 12.8% from its current market size of around $1.22 trillion in 2022 to $3.21 trillion by 2030. Due to benevolent government initiatives, the biotechnology industry is expanding quickly in developing nations like India, China, and Japan.
Additionally, the necessity for developing new vaccinations and diagnostic techniques to fight the disease grew during the Covid-19 epidemic. AstraZeneca, Gilead Sciences, Inc., Bristol-Myers Squibb, Sanofi, and Biogen are a few well-known businesses that have a substantial market share in the biotechnology sector.
The Founders and team
Founder: Osman Kibar
CEO: Cevdet Samikoglu
About Osman Kibar
The founder and Executive Chairman of Biosplice Therapeutics is Osman Kibar. In addition to a B.A. in mathematics and economics from Pomona College, he also holds a B.S. in electrical engineering from Caltech. He also earned his M.S. and Ph.D. in Biophotonics and Optoelectronics from the University of California, San Diego. Entrepreneur and inventor Osman developed numerous prosperous businesses, such as Genoptix, Dynamic Connections, and E-Tenna.
About Cevdet Samikoglu
The CEO of Biosplice Therapeutics is Cevdet Samikoglu. From Hamilton College, he received a B.A. in Economics, and the Harvard Business School awarded him an MBD. Cevdet is a former co-founder and co-portfolio manager of Greywolf Capital Management as well as a former director of research at Goldman Sachs. He served as CFO and President of Biosplice Therapeutics prior to being named CEO.
Team
Chief Financial Officer: Erich Horsley
Chief Medical Officer: Yusuf Yazici
Chief Legal Officer: Scott W. Bulcao
More than 120 people work at Biosplice Therapeutics.
The Beginning of Biosplice Therapeutics
Osman Kibar established Biosplice Therapeutics in 2008. In 2008, Osman relocated to San Diego and founded the biotechnology business Wintherix. Later, he changed the company’s name to Samumed.
The business made a big splash in 2016 with a $220 million war fund, a promising pipeline of anti-aging drugs, and a staggering valuation of about $12 billion in 2018. Additionally, in 2021, after putting another $120 million into its bank account, it secretly changed its name to Biosplice Therapeutics.
In 2015, Biosplice Therapeutics enrolled participants in a Phase II clinical trial for the treatment of osteoarthritis of the knee, which was successfully completed in 2017. Additionally, the business finished a Phase I Study for Potential Idiopathic Pulmonary Fibrosis Treatment in 2017. The publication of Lorecivivint’s Phase 2 results was announced by Biosplice Therapeutics for 2020. In 2022, it started the New Phase 3 Trial for Knee Osteoarthritis. At the European Society for Medical Oncology Meeting in September 2022, the company also unveiled fresh clinical data for Cirtuvivint.
Purpose and Aspirations
Delivering best-in-class medicines via alternative splicing, Biosplice Therapeutics seeks to restore health.
Products and Services
Clinical advancements made by Biosplice Therapeutics include:
- Cirtuvivint for various types of cancer
- Lorecivivint (in Phase 3) for osteoarthritis
- A wide range of degenerative diseases and disorders, including Alzheimer’s disease
Business Model of Biosplice Therapeutics
The scientific foundation of Biosplice Therapeutics is founded on biological insights guiding tissue specialization, enabling the business to target damaging proteins with tiny chemicals. By focusing on the CLK/DYRK family kinases, its fundamental discoveries in Wnt pathway modulation uncovered the expansive therapeutic potential of alternative splicing. These kinases are desirable, druggable targets within the cellular command and control centers because they affect the choice of tissue-specific and disease-selective mRNA splice sites.
By creating and commercializing regenerative medications for osteoarthritis, degenerative disc disease, lung tissue regeneration, articular cartilage injury, cancer, neurology, and other degenerative disorders, Biosplice Therapeutics generates revenue.
Investments and Financing
With the help of 5 investment rounds, Biosplice Therapeutics was able to secure $778 million. On April 15, 2021, the Venture Series Unknown Round, its most recent round of funding, was finished and a total of $120 million was raised. Eventide Asset Management, SymBiosis II, aMoon, Verition Fund Management, Sands Capital, and numerous more recent investors have supported Biosplice Therapeutics.
The value of Biosplice Therapeutics skyrocketed from $6 billion in 2016 to $12.8 billion in 2018.
FAQ’s
- Who are Biosplice Therapeutics’ biggest rivals?
Ans. Chordia Therapeutics, Twist Bioscience, Hopewell Therapeutics, Lycia Therapeutics, Endogena Therapeutics, and Bionaut Labs are the company’s main rivals.
- Who founded Biosplice Therapeutics?
Ans. Osman Kibar founded Biosplice Therapeutics in 2008.
- What is the work of Biosplice Therapeutics?
Ans. A clinical-stage biotechnology business called Biosplice Medicines creates first-of-their-kind, small-molecule medicines based on the cutting-edge study of alternative pre-mRNA splicing for serious disorders.
